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ABSTRACT: Human epidermal growth factor receptor 2 (HER-2) plays an essential role in cell growth and sur-
vival. HER-2 overexpression occurs in 20-30% of human breast tumors and has prognostic value as it is associ-
ated with disease progression. HER-2 overexpression is also associated with tumor progression and metastasis in 
malignant mammary tumors of the canine. However, in the literature, different positivity classifications/scoring 
were used in the evaluation of HER-2 status, and there is no consensus in terms of scoring of HER-2 expression 
in canine mammary tumors. In this study, it was aimed to estimate the HER-2 positivity rate by evaluating the re-
sults of the study using different positivity classifications by meta-analysis. In this context, by using ”HER-2 ca-
nine mammary tumor” keywords, Pubmed and Web of Science electronic databases were scanned until February 
2019, and a total of 97 related studies were found. However, 20 of these studies were used for the analysis. Two 
different meta-analyses were performed to evaluate the HER-2 positivity status with “2+ and 3+” and “3+” scores. 
As a result, HER-2 positivity rates were determined at 25.87% and 25.99% for the studies using “2+ / 3+” scores and 
“3+” respectively for HER-2 positivity. Therefore, this result suggests that the rate of HER-2 positivity is similar be-
tween humans and dogs.
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INTRODUCTION
Changes in growth factors, growth factor receptors, and other regulators of cellular proliferation play 
a role in tumorigenesis and therapeutic response in 
both canine and human mammary carcinomas (Araú-
jo et al., 2016). Human epidermal growth factor re-
ceptor 2 (HER-2), a member of the epidermal growth 
factor receptor (EGFR) family with tyrosine kinase 
activity, plays an important role in the regulation of 
cell growth, survival, and differentiation (Ressel et 
al., 2013). HER-2 overexpression is seen in 20-30% 
of human breast tumors and has a prognostic value, as 
it is associated with disease progression and shorter 
survival (Kim et al., 2011; Ressel et al., 2013). In ad-
dition to its prognostic value, analysis of HER-2 sta-
tus in human medicine is important for the selection 
of the patient who will undergo treatment (Ressel et 
al., 2013). HER-2 overexpression is associated with 
tumor progression and metastasis in canine malignant 
mammary tumors as well. However, the relevance 
of HER-2 overexpression and tumor progression or 
prognostic factors has not been clearly determined so 
it is controversial in canine mammary tumors, mainly 
due to variations in methods that are used in the eval-
uation of HER-2 expression status (Kim et al., 2011). 
One of the most important reasons for this situation 
is the low level of accuracy obtained with the com-
parison of results from different scoring systems. In 
studies concerning the role of HER-2 in canine mam-
mary tumor, there is no consensus in terms of scoring. 
Another important issue concerns the use of small 
sample sizes in studies making them of inadequate 
strength and consequently of limited validity and ac-
ceptability (Tas et al., 2018).
Meta-analysis is a method that can be used to 
solve such problems, and by combining similar study 
results, more general information about the popula-
tion parameter can be obtained by increasing the sam-
ple size (Avci, 2018). The aim of this study was to 
estimate the HER-2 positivity rate by analyzing the 
results of the studies with different scoring systems 
used in the examination of HER-2 positivity by me-
ta-analysis method. 
MATERIALS AND METHODS
For researching the effects of different HER-2 ex-
pression scoring in immunohistochemical analysis 
of malignant canine mammary tumors, Pubmed and 
Web of Science electronic databases were scanned up 
to February 2019 using the keywords “HER-2 canine 
mammary tumor” and 97 studies were accessed. The 
referees were blinded to the author and institution of 
the studies under investigation in determining the stud-
ies to be included in this research. A total of 20 studies 
were found suitable for analyses (Fig. 1, Table 1). 
Table 1. Studies and frequency distribution of score values for meta-analysis 
Study Frequency of score value (Score value:n) Sample Size
Nguyen et al., 2017 0: 262; 1+: 71; 2+:17; 3+:0 350
Damasceno et al., 2016 0: 1; 1+:14; 2+:22; 3+:6 43
Campos et al., 2015 0: 9; 1+:10; 2+:9; 3+:0 28
Silva et al., 2014 0: 2; 1+: 1; 2+:4; 3+:8 15
Dutra et al., 2004 0: 12; 1+:19; 2+:11, 3+:6 48
Ressel et al., 2013 0, 1+: 25; 2+,3+: 10 35
Im et al., 2012 0, 1+: 103; 2+,3+:36 139
Oh et al., 2012 0, 1+: 56; 2+,3+: 6 62
Kim et al., 2011 0, 1+: 34; 2+,3+:18 52
Kurilj et al., 2011 0, 1+: 46; 2+,3+: 5 51
Millanta et al., 2010 0, 1+: 36; 2+,3+: 10 46
Hsu et al., 2009 0, 1+: 64; 2+, 3+: 27 91
Gama et al., 2008 0, 1+: 79; 2+,3+: 21 100
Martín de las Mulas et al., 2003 0, 1+: 14; 2+, 3+: 3 17
Abadie et al., 2018 0, 1+, 2+: 350; 3+: 0 350
Araujo et al., 2016 0, 1+, 2+: 67; 3+: 6 73
Shin et al.,2015 0, 1+, 2+: 53; 3+: 34 87
Burrai et al., 2015 0, 1+, 2+: 7; 3+: 2 9
Muhammednejad et al., 2012 0, 1+, 2+: 23; 3+:12 35
Bertagnolli et al., 2011 0, 1+, 2+:61; 3+:10 71
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Records identified through initially database searching with 
“HER-2 canine mammary tumor” keywords up to February 2019 
Records after duplicates removed 
and screened 
n=70 
Reviews excluded: n=3 
Short communications excluded: n=2 
Case report excluded: n=1 
Letters to editor excluded: n=1 
Cell culture trials excluded: n=2 
Inaccessible papers: n=4
Full-text articles assessed for eligibility 
n=57 
Insufficient or in-extractable data excluded: n=8 
Out of scope (not mention HER2): n=29 
Studies included in meta analysis 
(total) 
n=20 
14 of records included in meta analysis for 
scoring HER-2 positive as 2+ and 3+
11 of records included in meta analysis 
for scoring HER-2 positive as 3+ 
Pubmed: n=59 Web of Science: n=38 
Figure 1. Flow chart showing the selection of studies for meta-analysis
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Studies in which HER-2 expression status was in-
dicated separately as a score (0, 1+, 2+, 3+) or was 
classified with scores clearly as “positive” and “neg-
ative” were included in the meta-analysis. Number of 
HER-2 positive and total number of cases were ex-
tracted from studies and used to calculate proportions 
(number of HER-2 positive/total number of cases) in 
the analysis. Different scoring systems were used in 
the studies evaluating HER-2 positivity. Studies that 
use three types of scoring systems were considered in 
this research. In the first type of studies, frequencies 
of scores were reported for 0, 1+, 2+ and 3+ scores 
separately (n=5). Furthermore, in the second type of 
studies, results were classified as negative for scores 
0 and 1+ and as positive for scores 2+ and 3+ (n=9). 
Finally in the third type of studies, only 3+ score was 
used to determine HER-2 positivity, whereas 0, 1+ 
and 2+ scores indicate HER-2 negativity (n=6). In or-
der to increase the number of publications included in 
analyses and thus, to obtain as much detailed infor-
mation as possible, two different meta-analyses were 
performed considering particularly two different scor-
ing systems. These meta-analyses were performed for 
second type of studies, indicating HER-2 positivity 
with 2+ and 3+ scores (n=14), and third type of stud-
ies indicating HER-2 positivity with 3+ score (n=11). 
Studies that use “0, 1+, 2+, 3+” scoring system (first 
type of studies) were used in both meta-analyses.
Statistical Analysis
 The publication bias of the studies was examined 
before the meta-analysis with Begg’s and Egger tests. 
Even if one of these tests is significant, it indicates 
that there is a publication bias; in this case, the trim 
and fill method was applied. The heterogeneity of 
the studies was evaluated with the Cochran Q test. In 
the evaluation of homogeneity and publication bias, 
α=0.10 was taken (Erdoğan and Kanık, 2011). Since 
heterogeneity was determined with the Cochran Q 
test, then DerSimonian Laird method was performed 
using the random effects model. For statistical anal-
ysis, “metafor” and “meta” packages were used in R 
version 3.5.3 software (R Development Core Team, 
2014). 
RESULTS
Evaluation of the studies that use 2+ and 3+ scores 
for HER-2 positivity
In dogs with mammary tumors, 14 studies classi-
fy HER-2 positivity based on immunohistochemical 
staining value of “2+ and 3+”. There was no publica-
tion bias according to the Egger test (p = 0.630) and 
Begg’s test (p = 0.956). Cochran Q test showed het-
erogeneity among studies (p<0.001; I2=89.4%). The 
meta-analysis results of the studies in which HER-2 
positivity is scored as 2+ and 3+ were given in Table 
2, and the related forest plot was shown in Fig. 2.
Table 2. Results of meta-analysis for studies in which HER-2 positivity is expressed with 2+ and 3+ scores
Study Positive Total Positivity Percent of HER-2 (%) 95% C.I.
Weight (%) 
REM
Damasceno et al., 2016 28 43 65.12 49.07-78.99 7.4
Campos et al., 2015 9 28 32.14 15.88-52.35 7.0
Ressel et al., 2013 10 35 28.57 14.64-46.30 7.2
Im et al., 2013 36 139 25.90 18.85-34.01 8.0
Oh et al., 2014 6 62 9.68 3.63-19.88 6.8
Kim et al.,2011 18 52 34.62 21.97-49.09 7.6
Millanta et al., 2010 10 46 21.74 10.95-36.36 7.2
Nguyen et al., 2018 17 350 4.86 2.85-7.66 7.8
Gama et al., 2008 21 100 21.00 13.49-30.29 7.8
Dutra et al., 2004 17 48 35.42 22.16-50.54 7.5
Silva et al., 2014 12 15 80.00 51.91-95.67 5.6
Kurilj et al., 2011 5 51 9.80 3.26-21.41 6.6
Hsu et al.,2009 27 91 29.67 20.55-40.16 7.9
Martín de las Mulas et al.,2003 3 17 17.65 3.80-43.43 5.6
Random Effects 219 1077 25.87 17.24-36.88 100
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Figure 2. Forest plot for studies in which HER-2 positivity is expressed with 2+ and 3+ scores
Evaluation of the studies that use 3+ score for 
HER-2 positivity
In dogs with mammary tumors, 11 studies classi-
fy HER-2 positivity based on immunohistochemical 
staining value of “3+”. Unlike studies that use “2+ 
and 3+”, there was publication bias in studies that 
use 3+ score for HER-2 positivity according to the 
Egger test (p = 0.014) and Begg’s test (p = 0.158). 
Because of the observed publication bias, trim and 
fill method was applied. However, the Cochran Q test 
demonstrated heterogeneity among studies (p<0.001; 
I2=88.4%). The meta-analysis results of the studies in 
which HER-2 positivity is scored as 3+ were given in 
Table 3 and the related forest plot was given in Fig. 3.
Table 3. Results of meta-analysis for studies in which HER-2 positivity is expressed with 3+ scores
Study Positive Total Positivity Percent of 
HER-2 (%)
95% C.I. Weight (%) 
REM
Damasceno et al., 2016 6 43 13.95 5.30-27.93 10.8
Araujo et al., 2016 6 73 8.22 3.08-17.04 10.9
Campos et al., 2015 0 28 0.00 0.00-12.34 4.7
Bertagnolli et al., 2011 10 71 14.08 6.97-24.38 11.4
Burrai et al., 2015 2 9 22.22 2.81-60.01 8.3
Muhammednejad et al.,2012 12 35 34.29 19.13-52.21 11.3
Shin et al., 2015 34 87 39.08 28.79-50.13 12.0
Nguyen et al., 2018 0 350 0.00 0.00-1.05 4.7
Dutra et al., 2004 6 48 12.50 4.73-25.25 10.8
Abadie et al., 2018 0 350 0.00 0.00-1.05 4.7
Silva et al., 2014 8 15 53.33 26.59-78.73 10.4
Random Effects 84 1109 12.96 6.47-24.27 100
Random Effects
(Trim fill was applied)
84 1109 25.99 13.49-44.16 100
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Figure 3. Forest plot for studies in which HER-2 positivity is expressed with 3+ score
DISCUSSION
There are many restrictions on research planning 
and implementation. The most effective of these con-
straints are cost and time. Cost and time constraints 
may prompt studies that use a relatively small num-
ber of cases. In addition to a large number of studies 
with a small number of cases, there also exist a few 
studies that use a large number of cases. Both of these 
situations may lead to conclusions with inadequate 
strength about population. To eliminate this concern 
and to ensure generalization in science, meta-analysis 
studies are used.
In this study, 20 out of 97 publications retrieved 
from Pubmed and Web of Science were found suit-
able for meta-analysis. Fourteen out of 20 studies 
employed 2+ and 3+ scores whereas 11 out of 20 em-
ployed 3+ score for HER-2 positivity. Five studies 
used “0, 1+, 2+ and 3+” scoring system for HER-2 
expression status; therefore, these studies were in-
cluded in both groups. Because two different scores 
were used for HER-2 positivity in the studies, two 
meta-analyses were performed to evaluate HER-2 
positivity in both situations.
Since the 2+ and 3+ scores were considered as 
HER-2 positive, the pooled proportion was 25.87%, 
and when the 3+ score was considered as HER-2 
positive, the pooled proportion was 25.99%. These 
two ratios can be considered as lower and upper lim-
its in estimating the population parameter. However, 
HER-2 positivity proportions of studies with 2+ and 
3+ scores ranged between 4.86% to 80.00%, and for 
3+ score ranged from 0.00% to 53.33%. This result 
indicates that HER-2 positivity rate varies consid-
erably in individual studies using different scoring 
systems. Therefore, the need for a meta-analysis of 
HER-2 positivity was justified. Moreover, given the 
relatively fewer number of studies (20 studies) that 
give detailed information about HER-2 positivity, a 
meta-analysis was needed to evaluate HER-2 positiv-
ity across studies better. 
Canine malignant mammary neoplasms are com-
mon tumors, and the prevalence varies from 26% to 
73% in female dogs and, in terms of morphology and 
biological behavior, represent a remarkably heteroge-
neous group of cancers (Burrai et al., 2015; Campos 
et al., 2015). Identification of diagnostic, prognostic, 
and therapeutic biomarkers is an urgent need to eval-
uate and manage this disease more effectively (Burrai 
et al., 2015). In addition to the estrogen and proges-
terone receptors, HER-2 is an essential biomarker for 
human breast cancer prognosis (Charpin et al., 1997; 
Ross and Fletcher, 1998). HER-2 overexpression is 
observed in 20–30% of human breast cancers (Slam-
on et al., 1989; Almasri and Al Hamad et al., 2005) 
but characterization of HER-2 expression and its as-
sociation with histologic type and tumor grading is 
controversial in canine mammary tumors (Kim et al., 
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2011; Kurilj et al., 2011).
HER-2 protein overexpression is observed in dif-
ferent percentages in canine malignant mammary 
tumors (19 to 74%) and this is related to a number 
of factors, including number of cases, different im-
munohistochemical methods, the sensitivity of the 
detection method, antibody used, the level of gene 
expression or the stages of tumor samples (Martín 
de las Mulas et al., 2003; Gouvea et al., 2006; Hsu 
et al., 2009; Kurilj et al., 2011; Oh et al., 2012). The 
most frequently used scoring system for HER-2 ex-
pression status is based on Hercept Test, but this 
system gives a significant number of false positives 
(Bertagnolli et al., 2011). Other methods (ASCO and 
CAP) established cut-off points for defining HER-2 
status. A threshold was adopted to avoid false posi-
tives, which is at least 30% of tumors (rather than the 
originally specified 10%). This ratio (%30) concerns 
the degree of membrane staining. If more than 30% 
of the total number of the neoplasmatic cells have 
their membrane uniform and intense stained immuno-
histochemically with the HER-2, then this neoplasm 
will be considered as positive for HER-2 (Bertagnolli 
et al., 2011). Moreover, Ressel et al. (2013) report-
ed that they could not compare their result, which 
was observed by another researcher due to the dif-
ferent scoring system. The prognostic significance 
and clinical importance of HER-2 status remain un-
clear in canine mammary tumors (Bertagnolli et al., 
2011). No relationship was identified between HER-2 
overexpression and tumor progression or prognostic 
factors (Martín de las Mulas et al., 2003; Hsu et al., 
2009; Kim et al., 2011; Ressel et al., 2013; Burrai et 
al., 2015). Moreover, Peña et al. (2014) reviewed that 
implication of HER-2 expression in canine mammary 
carcinogenesis was controversial and inconclusive. 
Thus, a standardized method is needed to obtain ob-
jective results for HER-2 overexpression status (Oh 
et al., 2012). Alternatively, the meta-analysis method 
may be used as a more suitable technique to evaluate 
the results of different studies that use different scor-
ing systems for HER-2 positivity.
CONCLUSIONS
In conclusion, according to the results obtained 
by the meta-analysis of studies that use two different 
scorings for HER-2 positivity, HER-2 positivity rate 
in dogs with mammary tumors ranges from 25.87% 
to 25.99%. Therefore, this result suggests that the rate 
of HER-2 positivity is similar between humans and 
dogs.
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